[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462509":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":25,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care","ACTIVE_COMPARATOR","Participants receive standard supportive care during hospitalization. No aromatherapy stick is provided.",[13],"Other: Standard of Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Aromatherapy + Usual Care","EXPERIMENTAL","Participants receive standard supportive care plus aromatherapy inhaler education and an aromatherapy stick for self-administered inhalation. Aromatherapy use occurs on the assigned Inhaler Use Day (targeted for Transplant Day +1, +2, or +3). Use is tracked with an inhaler use log. The aromatherapy \"dose\" is standardized by a maximum total exposure time (up to 2 hours total), while allowing participants to choose how to distribute use.",[19],"Other: Aromatherapy Stick",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Aromatherapy Stick","Participants receive aromatherapy inhaler education and an aromatherapy stick for self-administered inhalation during the early post-transplant inpatient period. Aromatherapy use occurs on the assigned Inhaler Use Day (targeted for Transplant Day +1, +2, or +3) and is documented using an inhaler use log. Total exposure is limited to a maximum of 2 hours.",[15],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Standard of Care","Participants receive standard inpatient supportive care during the acute post-HCT period. No aromatherapy inhaler is provided.",[9],[31],{"name":32,"affiliation":5,"role":33},"Anna Oh, PhD, MPH, RN","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","650-512-6691","aoh2@stanford.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Stanford","California","94305","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-122.16608,37.42411,{"lat":51,"lon":50},[54,55],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100462509","aromatherapy-inhaler-use-for-hsct-distress-100462509",false,"NCT05302583","Aromatherapy Inhaler Use for HSCT Distress","Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress","Inclusion Criteria:\n\n* Autologous and Allogeneic patients admitted to E1 for planned HSCT\n* Patients with hematologic malignancies requiring HSCT\n* No allergies to lavender or peppermint essential oils\n* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)\n* Adult patient over 18 years of age\n* Able to speak, read, and comprehend English\n* Willing and capable of providing informed consent\n\nExclusion Criteria:\n\n* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion\n* Patients receiving a transplant for a germ cell tumor diagnosis\n* Unexpected\u002Funplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)\n* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4\n* History of scleroderma\n* History of atrial fibrillation\n* Known history of G6PD deficiency\n* Allergic to lavender or peppermint essential oils\n* Pediatric patient 18 years of age or less\n* Unable to speak, read, and comprehend English\n* Unwilling or incapable of providing informed consent","ALL","18 Years",{"count":68,"type":69},50,"ESTIMATED","INTERVENTIONAL",[72],"NA","This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.",[75,76,77,78],"Cancer Distress","Cancer Coping","Hematopoetic Stem Cell Transplant","Aromatherapy","2026-05-29",{"date":81,"type":82},"2026-06-02","ACTUAL",{"date":84,"type":82},"2025-06-16",{"date":86,"type":69},"2026-06",{"name":5,"class":6},1]